File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: Importance of tumor biomarker in ablative therapies
  • Basic View
  • Metadata View
  • XML View
TitleHigh serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: Importance of tumor biomarker in ablative therapies
 
AuthorsPoon, RTP1
Lau, C1
Pang, R1
Ng, KK1
Yuen, J1
Fan, ST1
 
KeywordsHepatocellular carcinoma
Radiofrequency ablation
Tumor biomarker
Vascular endothelial growth factor
 
Issue Date2007
 
PublisherSpringer New York LLC. The Journal's web site is located at http://www.annalssurgicaloncology.org
 
CitationAnnals Of Surgical Oncology, 2007, v. 14 n. 6, p. 1835-1845 [How to Cite?]
DOI: http://dx.doi.org/10.1245/s10434-007-9366-z
 
AbstractBackground: Radiofrequency ablation (RFA) is a recently developed treatment for hepatocellular carcinoma (HCC). Thus far, the prognostic impact of tumor biomarkers has not been evaluated in this treatment. High serum level of vascular endothelial growth factor (VEGF) has been shown to predict microscopic vascular invasion and metastasis in HCC. This study investigated the prognostic significance of pre-treatment serum VEGF level in patients with HCC undergoing RFA treatment. Methods: Serum VEGF levels were measured using enzyme-linked immunosorbent assay in 120 patients with HCC undergoing RFA, and in 15 healthy controls. Serum VEGF levels were correlated with clinicopathological features of the HCC patients. The prognostic significance of serum VEGF levels was assessed by univariate and multivariate analyses. Results: The median serum VEGF level in the HCC patients was 240 pg/mL (range 17-1162), significantly higher than that of healthy controls (p = .024). The serum VEGF levels were significantly correlated with platelet counts (r = .487, p < .001) but not other clinicopathological features. Patients with serum VEGF level > 240 pg/mL had worse overall and recurrence-free survival compared with those with serum VEGF level > 240 pg/mL (p = .005 and .002, respectively). By multivariate analysis, serum VEGF level was a significant prognostic factor of both overall and recurrence-free survival. Conclusions: High pre-treatment serum VEGF levels predict poor prognosis after RFA of HCC. This study highlights the importance of tumor biomarker as a prognostic predictor in ablative therapy for HCC, which has an intrinsic problem of unavailability of histopathological prognostic features. © 2007 Society of Surgical Oncology.
 
ISSN1068-9265
2013 Impact Factor: 3.943
 
DOIhttp://dx.doi.org/10.1245/s10434-007-9366-z
 
ISI Accession Number IDWOS:000247470300009
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorPoon, RTP
 
dc.contributor.authorLau, C
 
dc.contributor.authorPang, R
 
dc.contributor.authorNg, KK
 
dc.contributor.authorYuen, J
 
dc.contributor.authorFan, ST
 
dc.date.accessioned2010-09-06T06:36:18Z
 
dc.date.available2010-09-06T06:36:18Z
 
dc.date.issued2007
 
dc.description.abstractBackground: Radiofrequency ablation (RFA) is a recently developed treatment for hepatocellular carcinoma (HCC). Thus far, the prognostic impact of tumor biomarkers has not been evaluated in this treatment. High serum level of vascular endothelial growth factor (VEGF) has been shown to predict microscopic vascular invasion and metastasis in HCC. This study investigated the prognostic significance of pre-treatment serum VEGF level in patients with HCC undergoing RFA treatment. Methods: Serum VEGF levels were measured using enzyme-linked immunosorbent assay in 120 patients with HCC undergoing RFA, and in 15 healthy controls. Serum VEGF levels were correlated with clinicopathological features of the HCC patients. The prognostic significance of serum VEGF levels was assessed by univariate and multivariate analyses. Results: The median serum VEGF level in the HCC patients was 240 pg/mL (range 17-1162), significantly higher than that of healthy controls (p = .024). The serum VEGF levels were significantly correlated with platelet counts (r = .487, p < .001) but not other clinicopathological features. Patients with serum VEGF level > 240 pg/mL had worse overall and recurrence-free survival compared with those with serum VEGF level > 240 pg/mL (p = .005 and .002, respectively). By multivariate analysis, serum VEGF level was a significant prognostic factor of both overall and recurrence-free survival. Conclusions: High pre-treatment serum VEGF levels predict poor prognosis after RFA of HCC. This study highlights the importance of tumor biomarker as a prognostic predictor in ablative therapy for HCC, which has an intrinsic problem of unavailability of histopathological prognostic features. © 2007 Society of Surgical Oncology.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationAnnals Of Surgical Oncology, 2007, v. 14 n. 6, p. 1835-1845 [How to Cite?]
DOI: http://dx.doi.org/10.1245/s10434-007-9366-z
 
dc.identifier.doihttp://dx.doi.org/10.1245/s10434-007-9366-z
 
dc.identifier.epage1845
 
dc.identifier.hkuros137545
 
dc.identifier.isiWOS:000247470300009
 
dc.identifier.issn1068-9265
2013 Impact Factor: 3.943
 
dc.identifier.issue6
 
dc.identifier.openurl
 
dc.identifier.pmid17406950
 
dc.identifier.scopuseid_2-s2.0-34249900712
 
dc.identifier.spage1835
 
dc.identifier.urihttp://hdl.handle.net/10722/71902
 
dc.identifier.volume14
 
dc.languageeng
 
dc.publisherSpringer New York LLC. The Journal's web site is located at http://www.annalssurgicaloncology.org
 
dc.publisher.placeUnited States
 
dc.relation.ispartofAnnals of Surgical Oncology
 
dc.relation.referencesReferences in Scopus
 
dc.rightsThe original publication is available at www.springerlink.com
 
dc.subject.meshCarcinoma, Hepatocellular - blood - surgery
 
dc.subject.meshCatheter Ablation
 
dc.subject.meshLiver Neoplasms - blood - surgery
 
dc.subject.meshTumor Markers, Biological - blood
 
dc.subject.meshVascular Endothelial Growth Factor A - blood
 
dc.subjectHepatocellular carcinoma
 
dc.subjectRadiofrequency ablation
 
dc.subjectTumor biomarker
 
dc.subjectVascular endothelial growth factor
 
dc.titleHigh serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: Importance of tumor biomarker in ablative therapies
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Poon, RTP</contributor.author>
<contributor.author>Lau, C</contributor.author>
<contributor.author>Pang, R</contributor.author>
<contributor.author>Ng, KK</contributor.author>
<contributor.author>Yuen, J</contributor.author>
<contributor.author>Fan, ST</contributor.author>
<date.accessioned>2010-09-06T06:36:18Z</date.accessioned>
<date.available>2010-09-06T06:36:18Z</date.available>
<date.issued>2007</date.issued>
<identifier.citation>Annals Of Surgical Oncology, 2007, v. 14 n. 6, p. 1835-1845</identifier.citation>
<identifier.issn>1068-9265</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/71902</identifier.uri>
<description.abstract>Background: Radiofrequency ablation (RFA) is a recently developed treatment for hepatocellular carcinoma (HCC). Thus far, the prognostic impact of tumor biomarkers has not been evaluated in this treatment. High serum level of vascular endothelial growth factor (VEGF) has been shown to predict microscopic vascular invasion and metastasis in HCC. This study investigated the prognostic significance of pre-treatment serum VEGF level in patients with HCC undergoing RFA treatment. Methods: Serum VEGF levels were measured using enzyme-linked immunosorbent assay in 120 patients with HCC undergoing RFA, and in 15 healthy controls. Serum VEGF levels were correlated with clinicopathological features of the HCC patients. The prognostic significance of serum VEGF levels was assessed by univariate and multivariate analyses. Results: The median serum VEGF level in the HCC patients was 240 pg/mL (range 17-1162), significantly higher than that of healthy controls (p = .024). The serum VEGF levels were significantly correlated with platelet counts (r = .487, p &lt; .001) but not other clinicopathological features. Patients with serum VEGF level &gt; 240 pg/mL had worse overall and recurrence-free survival compared with those with serum VEGF level &gt; 240 pg/mL (p = .005 and .002, respectively). By multivariate analysis, serum VEGF level was a significant prognostic factor of both overall and recurrence-free survival. Conclusions: High pre-treatment serum VEGF levels predict poor prognosis after RFA of HCC. This study highlights the importance of tumor biomarker as a prognostic predictor in ablative therapy for HCC, which has an intrinsic problem of unavailability of histopathological prognostic features. &#169; 2007 Society of Surgical Oncology.</description.abstract>
<language>eng</language>
<publisher>Springer New York LLC. The Journal&apos;s web site is located at http://www.annalssurgicaloncology.org</publisher>
<relation.ispartof>Annals of Surgical Oncology</relation.ispartof>
<rights>The original publication is available at www.springerlink.com</rights>
<subject>Hepatocellular carcinoma</subject>
<subject>Radiofrequency ablation</subject>
<subject>Tumor biomarker</subject>
<subject>Vascular endothelial growth factor</subject>
<subject.mesh>Carcinoma, Hepatocellular - blood - surgery</subject.mesh>
<subject.mesh>Catheter Ablation</subject.mesh>
<subject.mesh>Liver Neoplasms - blood - surgery</subject.mesh>
<subject.mesh>Tumor Markers, Biological - blood</subject.mesh>
<subject.mesh>Vascular Endothelial Growth Factor A - blood</subject.mesh>
<title>High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: Importance of tumor biomarker in ablative therapies</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=1068-9265&amp;volume=14&amp;issue=6&amp;spage=1835&amp;epage=1845&amp;date=2007&amp;atitle=High+serum+vascular+endothelial+growth+factor+levels+predict+poor+prognosis+after+radiofrequency+ablation+of+hepatocellular+carcinoma:+importance+of+tumor+biomarker+in+ablative+therapies</identifier.openurl>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1245/s10434-007-9366-z</identifier.doi>
<identifier.pmid>17406950</identifier.pmid>
<identifier.scopus>eid_2-s2.0-34249900712</identifier.scopus>
<identifier.hkuros>137545</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-34249900712&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>14</identifier.volume>
<identifier.issue>6</identifier.issue>
<identifier.spage>1835</identifier.spage>
<identifier.epage>1845</identifier.epage>
<identifier.isi>WOS:000247470300009</identifier.isi>
<publisher.place>United States</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong